Jupiter Wellness Inc. (NASDAQ: JUPW)

The QualityStocks Daily Newsletter would like to spotlight Jupiter Wellness Inc. (NASDAQ: JUPW).

New research has found that hearing issues are common among adultpatients who survive cancer. The study, conducted by researchersat UC San Francisco, discovered that more than one-half of cancer survivors whounderwent chemotherapy had significant hearing issues. Prior tothis, it was unknown how often survivors of lung, gastrointestinal,gynecologic or breast cancer suffered tinnitus and hearing loss. Tinnitus refers to ringing in the ears. For their study, the researchersrecruited 273 survivors, with an average age of 61. All individualsinvolved had concluded cancer treatment about five years before.The researchers discovered that roughly 35% of them experiencedtinnitus while more than 50% of them suffered significant hearingloss, which was confirmed by an audiogram.It is important for patients to notify their oncologist or primaryhealthcare provider about any hearing issues or tinnitus they mayexperience. Professional may be able to recommend helpful productson the market, such as those made by Jupiter Wellness Inc. (NASDAQ: JUPW) or other manufacturers.

Jupiter Wellness Inc. (NASDAQ: JUPW) is a diversified company that supports health and wellness by researching and developing over-the-counter (OTC) products and intellectual property. The company has a robust and growing portfolio of granted and pending patents to protect its proprietary products.

Jupiter Wellness’s product pipeline, backed by clinical research to ensure efficacy, addresses a range of underserved conditions. The company’s revenue is generated through a combination of OTC and consumer product sales, contract research agreements, and licensing royalties.

Jupiter Wellness was formed in 2018 and is headquartered in Jupiter, Florida.

Products with Purpose

Jupiter Wellness’s product pipeline currently targets a variety of indications with underserved needs. These include:

• Hair Loss – Jupiter Wellness’s Minoxidil Booster is a topical treatment that’s been clinically shown to increase the enzymes needed for minoxidil to work by up to 7x over a two-week period. The product has been licensed to Taisho, a $2.6 billion revenue company and Japan’s leading seller of minoxidil products, which expects to launch it commercially in 2023. The product is licensed to India-based Cosmofix Technovation Pvt. Ltd. and Sanpellegrino Cosmetics, and additional licensing opportunities are being pursued.
• Psoriasis & Vitiligo – Photocil safely and effectively permits phototherapy treatments at home by blocking harmful radiation and permitting the passage of therapeutic UV radiation. The product has been licensed abroad and is currently being launched commercially in India by Eris Oaknet Healthcare and Cosmofix Technovation under the brand name PhotoFirst. The product is also available in the U.S., and the company is working to find new partners in dermatology for expanded distribution.
• Jellyfish Protection Sunscreen – NoStingz is a topical protection from jellyfish, sea lice, and UVA/UVB rays. It provides an effective barrier against the stinging mechanism of jellyfish cnidocytes, preventing the delivery of venom to the victim. NoStingz is currently available online through Amazon and Walmart, as well as in select stores.
• Eczema – JW-100 is a pre-revenue topical treatment for atopic dermatitis (eczema). In prior studies, JW-100 cleared or reduced eczema symptoms following 2 weeks of use. Results suggest that JW-100 may potentially prove superior to existing prescription drugs. It is currently being evaluated in a Phase 3, double-blind, placebo-controlled multicenter trial.
• Burns – JW-300 is a pre-revenue topical treatment for first-degree burns and sun exposure. In prior studies, JW-300 was shown to significantly lower the incidence of burns in patients exposed to UV radiation. It is currently being evaluated for sale as an “after sun” consumer product.
• Cold Sores – JW-400 is a pre-revenue topical treatment of herpes labialis (cold sores). A phase 1, double-blind, placebo-controlled investigational study is currently being planned for JW-400.
• Sexual Wellness – JW-500 is a pre-revenue topical treatment for female libido loss. In clinical studies, the topical formulation improved nipple sensitivity and alleviated associated sexual problems. Jupiter Wellness plans to file for a pre-IND meeting with the U.S. FDA within the next 12 months and intends to seek Orphan Drug Designation.
• COVID-19-Induced Tinnitus – JW-600 is currently being evaluated in a triple-blind clinical study. Up to 15% of patients recovering from COVID-19 have experienced post-acute COVID-19-induced tinnitus

Management Team

Brian John is the CEO of Jupiter Wellness. For the past 20 years, he has been an investor and advisor to companies around the globe. He is the founder of a successful financial consulting firm specializing in helping emerging growth companies and has worked with hundreds of companies in dozens of countries over the last 25 years. Mr. John also serves on the board of directors of The Learning Center at the Els Center of Excellence – a school for children with autism in Jupiter, Florida.

Doug McKinnon is the CFO of Jupiter Wellness. His 35+ year professional career includes financial, advisory, and operational experience across a broad spectrum of industry sectors, including oil and gas, technology, cannabis, and communications. He has served in C-Level positions in both private and public sectors, including as chairman and CEO of an American-stock-exchange-traded company; as VP – Chief Administrative Officer of a $12-billion-market-cap Nasdaq-traded company; as CFO of several publicly-held U.S., Canadian and Australian companies; and as CEO/CFO of various other private enterprises.

Dr. Glynn Wilson is the Chief Scientific Officer of Jupiter Wellness. He brings to the company an extensive background of success in corporate management and product development with tenures in both multinational and start-up biotech organizations. He was formerly Head of Drug Delivery at SmithKline Beecham Pharmaceuticals; Research Area Head in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals; and Founder, CEO, and Chairman of TapImmune Inc., which became Marker Therapeutics through a merger. At TapImmune, he licensed cancer vaccine technology platforms and established the clinical pipeline.

Jupiter Wellness Inc. (NASDAQ: JUPW), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

• Jupiter Wellness Inc. (NASDAQ: JUPW) - Study Finds That Tinnitus, Hearing Loss Are Common in Cancer Survivors
• Everything You Need to Know About Postpartum Hair Loss
• Study Shows Gender Disparity in Sexual Health Counseling of Cancer Patients

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

• Cepton unveiled its Vista(R)-X120 Plus earlier this year at CES2023, one of the largest tech tradeshows this year, where it wasnamed a CES 2023 innovation award honoree for next-generation lidarproducts

• Vista(R)-X120 Plus features a wider field of view,software-definable regions of interest, and faster datatransmission with a target price below $500, enabling high-volumeproduction and faster mass-market adoption

• Vista(R)-X120 Plus is smaller and lighter, allowing for seamlessintegration without significantly affecting vehicle design

• Cepton collaborates with many global OEMS, and recently won thelargest commercial lidar deployment contract in the tolling sectorto date

Advanced Driver Assistance Systems (“ADAS”) make roads safer byusing sensors, cameras, and other technology to control speed,monitor blind spots, prevent collisions, and automate emergencybraking. While the technology has advanced rapidly in recent years,some challenges remain, including data integration from multiplesystems, information processing power and speed, and sensorreliability and accuracy.Cepton’s (NASDAQ: CPTN) latest automotive-grade lidar solution — the Vista(R)-X120 Plus —addresses those challenges and features improvements that set newstandards for perception technology.

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

• Reliability – The durable design uses common, easily attainable materials.
• Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
• Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
• Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Friday's trading session at $0.4, up 3.1726%, on 454,186 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.64/$.

Recent News

• Cepton Inc. (NASDAQ: CPTN) - Lidar Pioneer Cepton, Inc. (NASDAQ: CPTN) Bridges Technological Gaps to Advance Mass Market ADAS Adoption
• InvestorNewsBreaks - Cepton Inc. (NASDAQ: CPTN) Unveils Ultra-Slim, High Performance Automotive Lidar - the Vista(R)-X90 Plus
• Cepton, Inc. (NASDAQ: CPTN) Announces 2022 Financial Results With 65% YoY Growth in Revenues

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

•BiondVax Pharmaceuticals is a biotechnology company developing,manufacturing, and commercializing innovative NanoAbimmunotherapeutic products, primarily for the treatment ofinfectious diseases and autoimmune diseases

•Company CEO Amir Reichman recently presented at the BIO-EuropeSpring conference, where he talked about BiondVax’s successfulpreclinical in vivo results of its innovative inhaled COVID-19treatment and additional pipeline plans

•The in vivo results have shown that the company’s inhaled COVID-19therapy, formulated using alpaca-derived nanosized antibodies(“NanoAbs”), resulted in milder and shorter illness, virtuallyeliminated the virus from the lungs, and prophylactically protectedagainst illness

•Since he was appointed CEO in early 2021, Reichman has overseen theadoption of a de-risked strategy that entails developing andcommercializing biobetter NanoAbs with known mechanisms of actionand fully validated target molecules

•The company aims to address diseases with underserved medical needsand attractive large market commercial opportunities

Amir Reichman, CEO of biotechnology company BiondVax Pharmaceuticals (NASDAQ: BVXV), recently presented at the 17th annual BIO-Europe Springconference in Basel, Switzerland. Hosted by EBD Group, thethree-day in-person conference, which was held March 20-22, broughttogether more than 2,800 executives from biotech, pharma, andfinance companies. It not only featured presentations and exhibitsfrom some of the most promising companies in the biotechnologyspace but also allowed these companies to engage in more than15,000 one-on-one meetings with the attendees (https://ibn.fm/hbDbu).

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturingand commercializing innovative immunotherapeutic products primarilyfor the treatment of infectious and autoimmune diseases. “In manycompelling ways, BiondVax punches well above its weight compared tobiopharma companies of similar market cap: BiondVax gainedextensive drug development expertise [through previous clinicaltrials evaluating the M-001 universal influenza vaccine candidate],which is expected to be invaluable in the development andcommercialization of the NanoAb pipeline. The company plans toundertake the first-in-human phase 1/2a clinical trial evaluatingits inhaled anti-COVID-19 NanoAb therapy later this year. Thisrapid development path hinges not only on the expertise of itsworkforce and experience gained from the development of M-001 butalso on its capabilities in biological drug development andmanufacturing,” a recent article reads. “BiondVax believes that itsextensive drug development expertise, experienced leadership,manufacturing capabilities, and product and platform pipelineideally position it for in-licensing, acquisitions and jointventures, as well as rapid clinical development and manufacturingof new therapeutic and prophylactic technologies, beginning withthe inhaled anti-COVID-19 NanoAb candidate. By leveragingexpertise, experience and collaboration, BiondVax aims to disrupthigh-value large market opportunities with its pipeline ofinnovative NanoAb therapeutics.” To view the full article, visit https://ibn.fm/eHA4H

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

• NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
• NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Friday's trading session at $1.79, even for the day, on 52,293 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.70/$17.60.

Recent News

• BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) - BioMedNewsBreaks - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Innovative NanoAb Pipeline to Disrupt High-Value Market Opportunities
• BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Discusses Positive Results from In Vivo Proof-of-Concept Study of Its Anti-COVID-19 NanoAb Therapy and Additional Pipeline Plans at BIO-Europe Spring
• Eczema or Asthma Predisposes Individuals to Osteoarthritis

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

The 2023 Maryland General Assembly recently reached the policy goal the state has been edging towardfor years, approving regulations for recreational marijuana sales.Maryland residents aged 21 years and older will be able to purchaserecreational marijuana starting on July 1, 2023, if Governor WesMoore signs the legislation into law, which he is certain to do.Cannabis was made legal in the state constitution by a ballot referendum that was approved byvoters in November. Legislators promptly carried out theirdirectives, prioritizing the historic reforms at the top of theirto-do list even before the first session. The comprehensivelegislation established a framework for governmental monitoring andresolved a number of business-related issues, such as the types andnumber of marijuana licenses that can be issued as well as theamount of sales tax that must be charged by businesses. Overall,politicians from both chambers worked together to achieve two key objectives: stop unlawful salesbefore the deadline of July 1, 2023, and restore tax income andeconomic opportunity to areas that have been disproportionatelydisadvantaged by marijuana prohibition and punishment. Each purposeis interwoven throughout the entire 100-page document. As cannabisproduction ramps up to meet the growing demand for recreationalmarijuana in the state, plenty of opportunities will be created fornumerous ancillary companies that follow in the footsteps ofentities such as Advanced Container Technologies Inc. (OTC: ACTX), which specialize in availing what cannabis industry players needto serve their clients.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Friday's trading session at $0.3, even for the day, on 46 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.073/$1.25.

Recent News

• Advanced Container Technologies Inc. (OTC: ACTX) - 420 with CNW - Maryland Legislators Finalize Details of Recreational Marijuana Sales Launch
• 420 with CNW - Cannabis Prices Slump in Massachusetts Amid Supply Glut
• 420 with CNW - Colombian Authorities Seize More Than 8,000 Pounds of Marijuana in Maritime Operations

Battery Mineral Resources Corp. (TSX.V: BMR) (OTCQB: BTRMF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: BMR) (OTCQB: BTRMF).

Battery Mineral Resources Corp. ( TSXV: BMR ) ( OTCQB: BTRMF )(“ Battery ” or “ BMR ” or the “ Company ”) is very pleased toannounce that its senior executives will be attending the Centro deEstudios de Cobre y la Mineria (“ CESCO ”) event in Santiago Chilethe week of April 17 ^th to 21 ^st . CESCO Weekand the World Copper Conference provide some of the most importantcommercial and networking opportunities in the mining industry,attracting in excess of 2000 delegates. Both events are renownedfor the calibre of delegates and attract CEO participants from theworld’s most important miners and smelters.

BMR is also pleased to announce that it has entered into interestsettlement agreements with certain holders of convertibledebentures of the Company (the “ Debenture Holders ”) for thepayment of accrued interest owing under convertible debenturespreviously issued by the Company during 2022 by way of issuance ofcommon shares of the Company. Pursuant to these agreements, BMR hasagreed to issue an aggregate of 5,202,902 common shares(“ Shares ”) to settle C$830,038 of accrued interest owing toDebenture Holders (collectively, the “ Interest SettlementTransactions ”) as follows:

• 1,575,758 Shares at a deemed price of C$0.165 per Share.

• 294,300 Shares at a deemed price of C$0.19 per Share.

• 2,194,800 Shares at a deemed price of C$0.14 per Share; and

• 1,138,044 Shares at a deemed price of C$0.18 per Share.

Max Satel, CFO of BMR, commented: “We are pleased to have receivedthe continued support of our Debenture Holders, who have agreed toaccept their first-year interest in the form of Shares. This willfurther assist the Company in deploying its capital resourcestowards early re-start activities at the Punitaqui project.”

Battery Mineral Resources Corp. (TSX.V: BMR) (OTCQB: BTRMF) is a battery minerals company providing shareholders exposure to the global mega-trend of electrification while being focused on growth through cash-flow, exploration and acquisitions in favorable mining jurisdictions.

The company’s mission is the discovery, acquisition and development of battery metals (namely copper, cobalt, lithium, and graphite) in North America, South America and South Korea. It aims to become a leading low-cost producer of high quality, ethically sourced battery metals from high-grade, low impact mines in stable jurisdictions that are close to major consumer industries.

BMR is headquartered in Vancouver, British Colombia, with a portfolio of projects spanning Canada, the U.S., Chile and South Korea.

Project Portfolio

BMR’s current focus is the restart of its Punitaqui copper mine in Chile, as well as the exploration and development of its cobalt, lithium and graphite assets in North America and South Korea. The company also continues to identify and evaluate new project opportunities in its operating jurisdictions.

Its current portfolio includes:

Chile – Copper

BMR’s 100%-owned Punitaqui copper mine, acquired in March 2021, has the potential to generate an annual EBITDA of up to $50 million at or above a copper price of $4.25/lb. The company’s flagship project, the Punitaqui mine has been the subject of numerous milestones in recent months, including:

• BMR funded and completed a successful 32,526m resource drill program in 2022. Metallurgical testwork has confirmed the ability to produce excellent copper concentrates from each of the five zones tested, including recoveries ranging from 81% on the low end at Cinabrio Norte up to 96.5% at the Dalmacia deposit.
• The company in August 2022 reported the results of its first ever NI 43-101-compliant resource estimate for the underground deposits at its Punitaqui copper mining complex of 6.2 million tonnes grading 1.14% Cu in indicated category, along with 3.1 million tonnes grading 0.93% Cu in the inferred category. This resource estimate greatly exceeded management goals.
• In September 2022, BMR announced the approval by the Chilean Environment Assessment Service for the Environmental Impact Declaration (“DIA”) pertaining to mining at the company’s Cinabrio mine and San Andres deposit. The approval of the DIA allows BMR to move forward with starting mining operations in 2023 and restarting the mill at its Punitaqui copper mining complex soon after.
• BMR is focused on securing the final funding for the restart of mining and resumption of copper concentrate production at Punitaqui. Once this funding is received, BMR aims to complete mine rehabilitation and development in four to six months, with the ramp up from first production to the full production rate of 20-25 million pounds of copper in concentrate per annum to require a further four to six months.

“From exploration, engineering, community and permitting successes to realizing several non-dilutive means of funding to allow BMR to advance the project, our team looks forward to taking advantage of the renewed positive market sentiment for near term copper pricing and placing ourselves in a strong position to participate in a robust copper sector in 2023,” CEO Martin Kostuik stated in a news release.

Canada – Cobalt/Silver

Between 2016 and April 2018, BMR acquired through claim staking, option, joint venture and direct purchase the largest regional land holding in the historic home of high-grade cobalt-silver veins in Canada known locally as the Cobalt Embayment.

As of February 2023, BMR controlled a land package totaling 9 properties with 4,086 tenements that encompass an area of 84,003.39Ha. The key projects within the land package include McAra, Gowganda, Elk Lake, Fabre and Wilder. From 2017-2022, a total of 412 holes/51,452.34m were drilled on eight projects/20 targets. In addition, a total of 26,709 Line-Km of airborne geophysical surveys & 1,324.84sqkm of LiDAR topography was flown. Follow-up ground geophysical surveys resulted in a total of 37 surveys (514.64 Line-Km) being completed.

Initial NI 43-101 compliant resource defined at McAra (M&I Resource of 1,124,000lbs Co) was detailed in a Technical Report on Cobalt Exploration Assets in Canada dated as of February 5, 2021, with an effective date of October 31, 2020, prepared by SRK Consulting – G Cole PGeo (APGO#1416).

Idaho – Cobalt

BMR holds the Bonanza and East Fork properties located in the historic cobalt-copper-gold Blackbird mining district (Blackbird Mine from 1902-1963 produced 17Mt grading 0.7% Co, 1.4% Cu, and 1 g/t Au) located about 30 kilometers west of Salmon, Idaho. The Bonanza project is immediately adjacent to Jervois Global’s Idaho Cobalt Operations, the United States’ only operating primary cobalt mine. At Bonanza, there are seven mineralized sites within an area over three kilometers wide that extends along a gabbro dyke striking continuously for over six kilometers northward from Noranda’s historic Blackbird Cobalt/Copper mine. The showings on the project are Bonanza Copper Tunnels, Tinker’s Pride, Bonanza Copper #25, Indian Creek, Gray Copper, Blackrock #4 and Papoose #’s 1-4.

From 2018-2021, BMR’s Bonanza Exploration included 550 line-km of airborne magnetics and radiometrics followed up by surface exploration that included rock sampling, soil sampling, channel sampling of historic workings and 3.6km of time domain induced polarization geophysics.

The two properties cover 12 significant cobalt-copper prospects within the known mineralized zone. Both of the BMR Idaho cobalt belt properties host excellent high-grade discovery potential.

South Korea – Graphite

BMR has 100% ownership of the Guemam and Taehwa graphite exploration projects containing high-purity flake graphite deposits. Both assets are past-producing mines with existing local infrastructure and near-term production potential.

Nevada – Lithium

The company’s Amargosa lithium project is in the southern Basin & Range province and central Mojave Desert of Nevada. It is an early-stage exploration opportunity in a favorable region that hosts numerous lithium occurrences, including the Clayton Valley lithium deposit owned by Cypress Development Corp., as well as a major nearby lithium brine mine currently in production called the Silver Peak mine held by Albermarle Corp., one of the world’s largest lithium producers.

Market Opportunity

Near-term forecasts for the copper sector are extremely bullish, with stalwart Wall Street firms such as Goldman Sachs and Bank of America projecting record highs in the coming months. A combination of short-term supply deficits and long-term energy transition demand are expected to buck the downward pressures that have impacted copper prices in recent years.

Goldman in December 2022 forecast a 178K metric ton deficit in the copper market in 2023, causing the firm to raise its 12-month target to $11K/ton and its average price for calendar 2023 to $9,750/ton.

With China likely to continue accelerating efforts to restock depleted inventories in the wake of its COVID-19 reopening and a sustained push toward electrification around the globe placing a strain on supply, BMR is uniquely positioned to capitalize through the anticipated restart of operations at its Punitaqui copper mine.

Management Team

JMartin Kostuik is CEO and a Director of BMR. He brings to the company nearly three decades of diversified experience in the mining industry as a mining engineer and senior executive. Prior to joining BMR, Mr. Kostuik served as president and director of Arizona Gold Corporation and as CEO and director of Rupert Resources Limited. He built a broad base of experience in operations, engineering, exploration and capital projects with various companies including Luna Gold (Equinox), Barrick Gold Corporation, Taseko Mines Limited and DMC Mining Services. Mr. Kostuik earned his B.S. in Mining Engineering from Queen’s University and his M.B.A. from the University of Tennessee.

JMax Satel is the company’s CFO. He has over 18 years of experience as a successful natural resources-focused executive, most recently serving as EVP Corporate Development & Investor Relations for Arrow Exploration Corp., a TSX Venture- and AIM-listed oil & gas company with operations in Colombia and Canada. Prior to joining Arrow, Mr. Satel was principal and co-founder of Bordeaux Capital Inc., a Toronto-based advisory firm focused on the capital needs of companies across the natural resources sector, where he led and executed project financing advisory mandates involving global financial institutions and private equity funds. He earned a Bachelor of Commerce in Finance and Economics from the University of Toronto.

Jacob Willoughby is VP Corporate Development & Strategy for BMR. He brings to the company nearly 17 years of diversified experience in mining capital markets, including over eight years as a mining analyst covering exploration and development companies globally in both precious and base metals. Mr. Willoughby was most recently Vice President of Research and Analyst at Red Cloud Securities in Toronto. He spent two years as President and Director of Aldridge Minerals, a former Canadian based public exploration and development company with assets in Turkey and Papua New Guinea. Mr. Willoughby earned both a B.S. in Geology and a Masters in Business Administration from the University of Windsor.

FingerMotion Inc. (BTRMF), closed Friday's trading session at $0.14695, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0355/$1.05.

Recent News

• Battery Mineral Resources Corp. (TSX.V: BMR) (OTCQB: BTRMF) - Battery Mineral Resources Corp. announces attendance at CESCO week in Santiago Chile and interest settlement transactions with holders of convertible debentures
• InvestorNewsBreaks - Battery Mineral Resources Corp. (TSX.V: BMR) (OTCQB: BTRMF) Reports Community, Social Initiatives; Grants PSUs
• Battery Mineral Resources Corp. Announces an Update on Community and Social Initiatives at the Punitaqui Project in Chile and Grant of PSU

GeoSolar Technologies Inc.

The QualityStocks Daily Newsletter would like to spotlight GeoSolar Technologies Inc.

GeoSolar Technologies (“GST”), a Colorado-based climate technology company, is working to makeeveryone more energy-secure by utilizing the power of renewables.“With inflation at record-high levels and the risk of energydependence and climate crisis becoming even more threatening,GeoSolar seeks to combine the power of solar and geothermal tooffer American homeowners solutions that can help them achieveenergy security as well as save money and the planet at the sametime,” a recent article reads. “Technologies like wind, solar andbattery storage are growing rapidly each year – in 2023, theyaccounted for 82% of the new, utility-scale generating capacity theU.S. developers plan to bring online. Although, another renewableappears to be bursting onto the green energy scene, attracting agrowing public interest. It is geothermal energy, a potent cleanpower source that is still often called the lesser-known renewablecousin of wind and solar… That is exactly the power that GeoSolaraims to tap into. Seeking to lead Americans toward a greenerfuture, GeoSolar developed the SmartGreen(TM) Home system thathelps them achieve energy stability and save money while helpingthe planet. In a home equipped with the SmartGreen(TM) system, thesun’s energy is utilized to generate electricity through solarpanels. Then, the stable temperature of the earth is used tomaintain the home at an optimum temperature throughout the seasons,while the company’s proprietary air purifying technology aims toensure safe and healthy air in the home.” To view the full article,visit https://ibn.fm/PzqVz

GeoSolar Technologies Inc. (“GST”) is a Colorado-based climate technology company and the creator of the Smart Green Home® system for newly built and existing residences and commercial buildings. The company is focused on revolutionizing the way we heat, cool and power homes with 100% natural energy sources. Its patent-pending integrated system harnesses energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels.

In a GST home, the sun’s energy is captured on the roof to generate all of the electricity required. Additionally, the consistent climate of the earth is used to keep the home at a perfect temperature year-round, and the company’s proprietary air purifying unit ensures that the air inside the home is safe and healthy.

GST’s home technology has been installed in multiple test homes in Colorado and achieved exceptional results, including some of the most impressive energy efficiency ratings (HERS) in the industry.

GeoSolar Technologies is currently accepting investment as part of a Regulation A+ offering. Everyone* can invest now for as little as $300. For more information, visit the company’s profile on Manhattan Street Capital and review its Offering Circular.

GeoSolar Technologies Inc. (“GST”) has been qualified by the U.S. Securities and Exchange Commission (SEC) to conduct a Regulation A+ capital raise. GST is already a publicly traded company who makes quarterly and annual filings with the SEC and is subject to quarterly PCAOB audits. This is the first time shares of GeoSolar Technologies are being made available for public purchase. Upon completion of this Regulation A+ offering, the company intends to seek a listing of its stock.

The Decarbonization Movement

Soaring and unstable energy/fuel costs continue to highlight the importance of rethinking the traditional approach to powering homes, from top to bottom. While most everyone is well aware of the remarkable, multi-trillion-dollar opportunity the electric vehicle transformation offers to investors (in addition to the benefits to the climate problem), few recognize that the all-electric home market is as large as electric vehicles and equally important to reducing carbon emissions.

U.S. energy expenditures clocked in at $3,891 per person in 2018, leading to estimated spending of $1.3 trillion on energy that year alone. Despite this, fewer than 3% of U.S. homes are currently powered by solar. This number is poised to increase exponentially as both new and existing residences transition to zero carbon models.

GST estimates that if all the homes in America were powered by its technology, carbon pollution could be reduced by an estimated 1.9 trillion pounds per year, greatly reducing the negative impacts on our climate.

GeoSolarPlus®

The GeoSolarPlus (“GSP”) system combines solar power, geothermal ground-sourced energy and other clean energy technologies into one fully integrated system.
Key benefits of the GSP system include:

• Making a real planet-changing difference in reducing air pollution
• Eliminating or significantly reducing homeowners’ future utility bills
• Enjoying lifetime energy independence and protection from price escalation and energy shortages
• Eliminating greenhouse gas emissions from operation of home and daily life
• Increasing home value
• An integrated design for seamless operation of renewable energy systems
• Maintaining a significantly healthier living environment
• Leveraging existing renewable energy tax credits and electrification incentives
• Creating stable jobs capable of supporting families in the decarbonized future

Click here to learn more about how GeoSolarPlus works.

Management Team

The GST leadership and management team includes some of the world’s most experienced and respected leaders in the fields of decarbonization and sustainable homes.

Stone Douglass is the Chairman and CEO of GST. He is a seasoned, 30-year public company executive and former Chairman and CEO of the Piper Aircraft Company.

Brent Mosbarger is the company’s Co-Founder and leads its commercial operations. He is a highly respected solar engineer whose experience includes roles with Chevron Energy’s green operations and serving as project manager and executive for a $400 million solar/geothermal innovation project.

Peter Romenesko is a Senior Strategic Advisor with GST. He brings to the company considerable experience as an engineer and large-scale project manager for Johnson Controls and Siemens.

Dr. Norbert Klebl is the company’s Co-Founder and Development Director. Recognized as one of the world’s leading experts in the field of zero-carbon innovation, he is a former McKinsey partner of 16 years with an MBA from Columbia.

Dar-Lon Chang is GST’s Director of New Product Development. Prior to joining GST, he had a 16-year career with ExxonMobil Energy Research. He received his PhD in engineering from the University of Illinois.

* Must be over 18, certain states are not currently available and will be added soon.

Recent News

• GeoSolar Technologies Inc. - QualityStocksNewsBreaks – GeoSolar Technologies Inc. Seeking to Combine Power of Solar, Geothermal on Path to a Greener Future
• GeoSolar Technologies Inc. Advances Home Renewable Systems That Reduce Carbon Use and Potentially Eliminate Utility Bills
• Green Housing Market Coast-to-Coast Creates Opportunity for GeoSolar Technologies Inc.

Coyuchi Inc.

The QualityStocks Daily Newsletter would like to spotlight Coyuchi Inc.

Coyuchi is a bed, bath and apparel product company and the gold standardin sustainable luxury home goods. “Coyuchi devotes its corporatepurpose to being ‘responsible beyond the thread’ – using cotton andlinen certified to the Global Organic Textile Standard (‘GOTS’),respected as the most rigorous around the world, and extendingbeyond that to product use and recycling considerations,” a recentarticle reads. “In addition to Sejal Solanki (chief marketingofficer), Marcus Chung (chief operating officer), Gabriela Bermudez(controller), and Priyadarshi Sinha (VP of technology), EileenMockus [Coyuchi’s president and CEO] leads an experienced team ofsustainable fashion design enthusiasts. Design Director WhitneyThornburg arrived in the industry from an education career whereshe developed and taught fashion design curricula in sustainablepractices and creating circular systems. After two years-longseasons working for a San Francisco clothing label, she joinedCoyuchi in 2019. Director of Sustainability and Sourcing MargotLyons played a direct role in Coyuchi’s achievement of fullcircularity – a term describing the use of design, recycling,reuse, remanufacturing, and refurbishment to create a closed loopsystem that eliminates waste and maximizes the reuse of resources….Brand Marketing Director Julie Wells and Director of OperationsIzzie Ali have similarly brought a drive for sustainable andeco-friendly business practices to the company with their arrivalsduring the past year, drawing on international educations as wellas their experiences in North American industry. Together, Coyuchicontinues to maintain and expand its earth-friendly brand.”

To view the full article, visit https://ibn.fm/S9YfL

Coyuchi is the gold standard in sustainable luxury home goods. The company offers sustainably produced luxury organic bedding, sheets, towels, apparel, and other home goods for the environmentally conscious home. With a timeless, coastal-inspired aesthetic, Coyuchi uses only 100% organic cotton materials to manufacture all of its textiles.

The Company was built upon four foundational pillars: protect the planet, innovate circular design, live sustainably, and enrich the community. These guiding principles have proven an effective market strategy. In 2021, Coyuchi earned $33.3 million in net sales, amounting to 26% YoY growth (the industry average is only 5%). It also experienced 2x customer growth to 200,000 active customers, averaging a 35% customer repeat purchase rate.

With a seasoned leadership team, a robust e-commerce shopping experience, and a healthy customer base that drives the fast-growing organic luxury market, Coyuchi is prepared to propel a new phase of growth as the rest of the world finally awakens to sustainability at scale.

A Lucrative Market Ripe for the Taking

The global market for organic bedding, which was estimated at $814.3 million in 2020, is projected to reach $1.1 billion by 2027, growing at a CAGR of 4.9% over that period, according to Research and Markets. More specifically, the domestic organic bedding market is estimated at $240.1 million in 2020, according to Statista. Overall, the U.S. market for home textiles is currently valued at $25 billion annually, and, with a forecast annual growth rate of 5%, it is expected to reach $30 billion by the end of 2025.

Grand View Research reported in 2020 that shifting consumer preference toward high-end lifestyle products is a key factor driving the growth of the organic bedding market. Seventy-four percent of consumers are willing to pay more for sustainable products – a consumer preference that has steadily increased over the last few decades. Millennials especially favor ethical consumption over price when purchasing goods and services, with 83% of millennials reporting that they want the brands they purchase from to align with their beliefs and values (https://ibn.fm/PANNV). With a majority millennial customer base, Coyuchi is poised to capitalize on this trend.

Industry Defining Sustainability Practices

For 30 years, Coyuchi has explored organic farming and sustainable textiles and guarantees the highest environmental and ethical standards through a number of certifications such as The Global Organic Textile Standard (GOTS), Fair Trade Certified, and MADE SAFE®.

Coyuchi continues to push the organic textile market forward through its circularity initiatives and by supporting cross-industry sustainability advocates. Coyuchi’s mission to bring beauty and comfort to every home without sacrificing the health of our planet has resulted in a number of important sustainability checks and balances.

• A Circular Business Model: Coyuchi has cultivated a holistic 360-degree approach that contributes to the fight against climate change with its take back and recycling program, 2nd Home™. In 2017, it became the first luxury home brand to implement such an initiative, and, since then, the company has eliminated 68,758 lbs. of toxic chemicals from homes and renewed 6,000 lbs. of textiles.
• The Coyuchi Climate Council: In early 2022, Coyuchi introduced a cross-disciplinary council with a goal of Net Zero Emissions by 2025 and Net Positive Emissions by 2030. The Coyuchi Climate Council brings together influential minds across fashion, regenerative farming, and sustainability who have the knowledge and experience necessary to achieve climate change.
• C4: The California Cotton & Climate Coalition: Most recently, Coyuchi announced it is a founding member of C4, which includes innovative, sustainable fashion, apparel, and personal care brands like MATE the Label, Outerknown, Reformation, and Trace. Working together pre-competitively, C4 creates a structure for investing in regionally grown, Climate Beneficial™ cotton and directly supports the livelihoods of the farmers that grew it. Coyuchi is the only home industry brand currently involved in the project.

Omnichannel Business Model

Coyuchi differentiates itself through an omnichannel and circular business model, both of which have proven a clear draw for customers. It was an early adopter of an e-commerce sales and marketing approach (over 80% of its sales are directly through coyuchi.com), creating a distinct advantage over incumbents and start-up newcomers in the luxury space. This has resulted in a high lifetime value customer, luxury retail partners such as Nordstrom, and a flagship store in Marin County.

Coyuchi’s Organic Textile Products

Coyuchi’s product assortment consists of consciously designed bedding, bath, apparel, and lifestyle products spread across about 1,400 SKUs. The company believes that its product assortment, produced from 100% organic cotton with Global Organic Textile Standard (GOTS) certification, provides it with a significant competitive advantage. GOTS is the world’s leading textile processing standard for organic fibers, ensuring the organic status of textiles after harvesting raw materials through environmentally and socially responsible manufacturing all the way to labeling, a major environmental and social benefit over conventional cotton product production.

Coyuchi’s focused product assortment consists of four core categories:

• Bedding – A full suite of sustainable, organic, and high-quality sheets, duvet covers, blankets, and throws.
• Bath – A luxurious line of towels, bath rugs, and mats.
• Apparel – Premium apparel for men and women, including robes, sweaters, pants, and pajamas.
• Lifestyle – The lifestyle category offers 135 SKUs, from organic napkins to crossbody totes.

Management Team

Eileen Mockus is President and CEO at Coyuchi. She has more than 25 years of experience in retail, having held positions in textile development at Patagonia, Pottery Barn Teen, and The North Face. She earned a bachelor’s degree in textiles and clothing from UC Davis and an MSBA from San Francisco State University.
Sejal Solanki is Chief Marketing Officer at Coyuchi. She previously served as the company’s Vice President of E-Commerce. Before joining Coyuchi, she worked at teen clothing giant Charlotte Russe. She oversees the company’s digital marketing, site experience, brand marketing, and e-commerce strategy.

Marcus Chung is Coyuchi’s COO, overseeing supply chain, sourcing strategy, sustainability, and IT. He previously held positions at notable direct-to-consumer brands Third Love and Stitch Fix, as well as national retailer The Children’s Place. He holds a bachelor’s degree from Wesleyan University and an MBA from UC Berkeley’s Haas School of Business.

Margot Lyons is Director of Sustainability and Sourcing at Coyuchi, where she works with strategic partners to ensure all the company’s product sustainability standards are met. She received a master’s degree in textiles and clothing from UC Davis.

Use of Proceeds

This round of funding will be used to increase Coyuchi’s enterprise value through expanded marketing, product category expansion, continued physical presence, and B2B strategic partnerships with wholesalers, and online marketplaces.

Recent News

• Coyuchi Inc. - InvestorNewsBreaks – Coyuchi Inc. Committed to Being ‘Responsible Beyond the Thread’
• Coyuchi Inc. Recently-Opened Palo Alto Store Helps Bring To Life The Coyuchi Luxury Experience
• Coyuchi Inc.’s Organic Bedding Collection Combines Coastal-Inspired Landscape Themes with Sustainable Cotton Material

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is increasing thebioavailability of and improving the way that active pharmaceuticalingredients (“APIs”) enter the bloodstream by promoting moreeffective oral delivery with its patented DehydraTECH(TM). “Mostrecently, a company announcement indicates that a just-completedDIAB-A22-1 diabetes study has produced at least three positiveoutcomes, including weight loss in obese diabetic-conditionedanimals and improved triglyceride and cholesterol levels. Theanimals tested in the study showed these dramatic changes in as fewas three days when dosed with DehydraTECH-processed cannabidiol(‘CBD’), aligned with other study work pointing to CBD’s knownanti-inflammatory and antioxidant properties. Lexaria is pleasedthat relatively low dosages of DehydraTECH-CBD seem to support realimprovements in the lab animals’ day-to-day health and findsencouragement in the positive results from its first diabetesstudy,” a recent article reads. “Since 2014, Lexaria has beendeveloping its patented DehydraTECH technology, which has yielded28 granted patents and many more pending in countries worldwide.DehydraTECH’s evidenced benefits include the improved speed ofonset, increased bioavailability, increased brain absorption, andreduced drug administration costs.”

To view the full article, visit https://ibn.fm/hJn4Y

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

• Speeds up delivery – the effects of the product are felt by the subject in just minutes.
• Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
• Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
• Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
• Reduces drug administration cost – lower doses mean lower overall drug costs.
• Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

• Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
• Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
• Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
• Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
• Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
• Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Friday's trading session at $2.18, off by 5.6277%, on 20,428 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.80/$4.83.

Recent News

• Lexaria Bioscience Corp. (NASDAQ: LEXX) - TinyGemsBreaks - Lexaria Bioscience Corp.'s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Positive Results in First Diabetes Study
• Lexaria Bioscience Corp. (NASDAQ: LEXX) Revolutionizing Drug Delivery Potential for Active Pharmaceutical Ingredients Using Patented DehydraTECH(TM) Technology
• Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Multiple Commercial Applications for Its Patented DehydraTECH(TM) Technology Platform

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

D-Wave (NYSE: QBTS), a leader in quantum computing systems, software and services, andthe only commercial provider building both annealing and gate-modelquantum computers, today announced financial results for its fourthquarter and fiscal year ended Dec. 31, 2022.

“We believe our fourth quarter and 2022 year-end results reflect aclear signal: companies are rapidly embracing today’s quantumtechnology solutions to drive competitive advantage, now. In thiscomplex economic environment, business leaders are actively lookingfor ways to improve operational efficiencies, reduce costs, fuelinnovation, and increase revenue. We believe that near-term quantumand quantum-hybrid applications are critical for navigating thiscomplexity by helping solve businesses’ most difficultcomputational problems. Our revenue metrics reflect increasingquantum adoption, which accelerated growth of our business anddrove a 41% increase in Q3 to Q4 sequential revenue growth,” saidDr. Alan Baratz, CEO of D-Wave.

“Sixty-seven commercial customers used D-Wave solutions in 2022,and we now count more than two dozen of the Forbes Global 2000 ascustomers, as an increasing number of companies turn to quantumcomputing to solve complex business problems ranging from customerloyalty to supply chain logistics to e-commerce optimization.Beyond our continued commercial traction, we’re driving ongoinginnovation and advancement of our product portfolio, most recentlyintroducing new offerings that help customers harness quantum toaccelerate artificial intelligence and machine learning efforts.We’re seeing accelerating momentum across all facets of ourbusiness. Finally, we are pleased to announce the closing of a $50million four-year term loan.”

To view the full press release, visit https://ibn.fm/y0nUy

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

• Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
• Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
• Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Friday's trading session at $0.5, off by 23.2776%, on 3,456,959 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.491/$13.23.

Recent News

• D-Wave Quantum Inc. (NYSE: QBTS) - InvestorNewsBreaks - D-Wave Quantum Inc. (NYSE: QBTS) Announces Q4 and Year-End 2022 Results
• InvestorNewsBreaks - D-Wave Quantum Inc. (NYSE: QBTS) Schedules Q4, FY 2022 Financial Report Release, Earnings Call
• D-Wave Quantum Inc. (NYSE: QBTS) Provides Practical Quantum Computing Solutions to Help Companies Improve Operational Efficiencies and Navigate Complexity

IGC Pharma Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight IGC Pharma Inc. (NYSE American: IGC).

Germany shipped an unprecedented 25,000 kilos (27.6 tons) of medicinal and experimental cannabis last year, up 19% from 2021, per the Federal Drug Institute andMedicinal Devices (BfArM). But it also represents the smallestincrease since BfArM started disclosing information on cannabisimports in 2018. Due to the potential for inferior products orre-exportation to various nations, a sizable fraction of theshipments may have failed to reach patients. The German NationalAssociation of Statutory Health Insurance Funds claims that theincrease in imports is also at odds with the constant statesubsidies for medical marijuana products, which have been steady since 2020. Industry sources also assert that the quantity of cannabis sentto pharmacies is far less than that which is shipped into Germany.Only eight tons of medicinal cannabis had been shipped topharmacies in Germany as of September 2022, a significant decreasefrom the 19 tons shipped during the comparable period the yearprior. It is notable that Germany currently allows the use ofcannabis for medical purposes. This recognition of the therapeuticvalue of marijuana has given rise to several for-profit entitiessuch as IGC Pharma Inc. (NYSE American: IGC) that are going a step further to develop pharmaceutical-gradeformulations from this plant.

IGC Pharma Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule (www.clinicaltrials.gov). As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products (www.Holief.com) such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand (www.SundaySeltzer.com) that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.

IGC-AD1

IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.

TGR-63

The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

IGC Pharma Inc. (NYSE American: IGC), closed Friday's trading session at $0.321, off by 3.3715%, on 119,213 volume. The average volume for the last 3 months is 119,213 and the stock's 52-week low/high is $0.2785/$0.87.

Recent News

• IGC Pharma Inc. (NYSE American: IGC) - 420 with CNW - German Cannabis Imports Grow to Record Levels
• 420 with CNW - Missouri Sees Uptick in Marijuana Jobs Shortly After Legalization Ballot
• 420 with CNW - Bipartisan Bill Before Congress Seeks to Force DEA to Allow Patient Use of Cannabis, Psychedelics

SideChannel Inc. (OTCQB: SDCH)

The QualityStocks Daily Newsletter would like to spotlight SideChannel Inc. (OTCQB: SDCH).

•Governments worldwide are pushing for the ban of TikTok fromgovernment devices, citing threats to national security

•Chinese company ByteDance, the owner and creator of TikTok,believes the ban is premature and has not had the opportunity toanswer questions relating to information security

•Haugli explains that default permissions, including location,contacts, media, and more, are required at the time of download –making it possible for ByteDance to store data and metadata thatcould pose a risk

Deteriorating relationships between China and other worldgovernments have raised concerns about how much data is shared onpopular social media apps like TikTok. TikTok is owned by theChinese company ByteDance, and the default permissions requiredwhen downloading the app include location, access to contacts,media, and more. Due to the app's data collection practices,governments are banning officials from downloading the app on theirdevices – citing a potential threat to national security.

SideChannel (OTCQB: SDCH) is a cybersecurity services and technology provider whose keyservice is providing virtual chief information security officers(“vCISOs”) on contract to small and medium-sized businesses(“SMBs”) without the budget capacity to hire their own full-timeCISOs. “SideChannel’s cybersecurity experts are presented toclients as guidance providers who can work in the boardroomalongside the companies’ leading officers. ‘The cybersecurityprofession is now akin to legal, accounting and insurance,’SideChannel CEO Brian Haugli said during a live company webcastrecently. ‘When we look inside organizations at the enterpriselevel, we see the CISO right there with HR (Human Resources), GC(General Contracting), Internal Audit, and other C-suite membersfor a reason. Because that’s how important it is for theorganization’s success to address cybersecurity as an operationalrisk at an enterprise level. And our clients are seeing it, andthey’re realizing the value that they’re getting out of it byworking with us,’” a recent article reads. “SideChannel also hasdeveloped a micro-segmentation security product named Enclave thatit offers either as a software-as-a-service (‘SaaS’) tool on asubscription basis, or as a managed service offering that exceedswhat is otherwise available throughout the industry.”

To view the full article, visit https://ibn.fm/Xpwa1

SideChannel Inc. (OTCQB: SDCH) simplifies cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time CISO.

SideChannel’s team of virtual Chief Information Security Officers (vCISOs) possesses a combined 400-plus years of experience in cybersecurity. They’ve honed their skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank and the Pentagon. SideChannel lends this talent to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for the growing enterprise.

SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help them protect their data and assets. To date, SideChannel has created more than 50 multi-layered cybersecurity programs for its clients.

Reports show that cyberattacks on SMBs have increased in recent years, as organizations’ network attack surfaces have grown exponentially with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications and third-party suppliers to conduct business.

SideChannel continues expanding its service offerings, workforce and customer base, attracting over 20 virtual CISOs to serve across industries including fintech, biotech, healthcare, manufacturing, legal, defense and technology services. The company is based in Worcester, Massachusetts.

Market Opportunity

An analysis from ReportLinker states that the global cybersecurity market is expected to grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving cyber security market growth, according to the report.

A lack of cybersecurity professionals and the budget constraints among SMBs and start-ups in developing economies are expected to hinder market growth. Cybercriminals are using automated techniques to attack SMBs’ networks to take advantage of their weak security infrastructures. To save money, time and resources, SMBs are seeking cybersecurity solutions.

Enclave

Enclave expands upon SideChannel’s cybersecurity service offerings by solving a pervasive network security problem with a simple tool.

A comprehensive cloud and network security solution, Enclave enables IT teams to contain breaches faster, reduce network outages, minimize latency and strengthen overall security defense.

Enclave creates the foundation for a Zero Trust network security model IT can build upon.

With Enclave, IT can easily segment their company’s network, organize personnel and computing devices at the employee workload level, and implement security controls across all network segments.

Enclave was designed and purpose built to serve the growing security needs of SMBs, a traditionally underserved market that is more prone to cyberattacks but has limited protection due to smaller budgets, inadequate IT security staffing and a lack of cybersecurity awareness among top executives.

Enclave is an affordable and effective network security solution that shrinks the attack surface area exposed to a cyber intruder and significantly reduces the amount of effort required to operate securely.

Management Team

Brian Haugli is CEO of SideChannel. He has led programs for the U.S. Department of Defense, the Pentagon, and Fortune 500 companies. He is an expert on National Institute of Standards and Technology guidance, threat intelligence implementations and strategic organizational initiatives. He is a professor at Boston College, Woods College of Advancing Studies Master’s Program in Cybersecurity. He is also a contributing author for the Wiley book ‘Cybersecurity Risk Management’.

Ryan Polk is CFO at SideChannel. He has been the principal of Perissos Partners, an executive consulting firm, since June 2017. He also served in executive roles in the portfolio companies owned by Lacy Diversified, with combined revenue approaching $2 billion. He served as the Vice President for Corporate Financial Planning and Analysis for Brightpoint, a publicly traded, Fortune 500 mobile device logistics company. He earned a bachelor’s degree in accounting and industrial management from Purdue University.

Nicholas Hnatiw is Chief Technology Officer at SideChannel. Prior to joining the company, he served as the technical director for network operations supporting U.S. Cyber Command, U.S. Intelligence Agencies and other Department of Defense research organizations. He was also the CEO of Loki Labs, a cyber security firm. He earned a bachelor’s degree in computer engineering and computer science at the University of Massachusetts, Amherst.

Bill Roberts is SideChannel’s CISO. He most recently served as the vice president, IS & CISO for Hologic Inc., a global medical device company, where he established cyber security and IT compliance programs. Prior to Hologic, he was vice president of information security for Cytyc Corporation, which was acquired by Hologic in 2007. At Cytyc, he managed global IT as the company grew from 140 employees to 1,500 and from $40 million in revenue to over $750 million.

SideChannel Inc. (OTCQB: SDCH), closed Friday's trading session at $0.0682, off by 1.934%, on 30,500 volume. The average volume for the last 3 months is 30,500 and the stock's 52-week low/high is $0.0412/$0.18.

Recent News

• SideChannel Inc. (OTCQB: SDCH) - SideChannel Inc. (SDCH) CEO Brian Haugli Discusses Government TikTok Ban in Forum Daily Interview
• TechMediaBreaks - SideChannel Inc. (SDCH) Helping Clients Address Cybersecurity at the Enterprise Level
• SideChannel Inc. (SDCH) Offers Unique Suite of Cybersecurity and Privacy Services On An As-Needed Basis for Optimum Affordability

Fintech Ecosystem Development Corp. (NASDAQ: FEXD)

The QualityStocks Daily Newsletter would like to spotlight Progressive Care Inc. (OTCQB: FEXD).

Fintech Ecosystem Development Corp. (NASDAQ: FEXD) is a special purpose acquisition company (SPAC) formed for the purpose of effecting one or more business combinations with an intent to focus on the financial technology sector.

The company’s mission is to create and grow a global financial services ecosystem to address unmet mobile money needs in developing and industrialized countries and markets. FEXD plans to achieve this by acquiring and merging with financial technology pioneers that have the potential to help establish its global fintech ecosystem, and by continuing the development of proprietary technologies and applications to keep the company at the forefront of the cashless society market.

Digital money is replacing physical cash. Consumers can buy products and services from anywhere in the world and make payments across borders. Parents can send money to students studying in other countries. Migrant workers are sending money to families in developing nations. Rural villagers without banks can send and receive money using their smartphones. FEXD is developing mobile transaction platforms, applications and services that are helping to implement these changes.

The company plans to offer a diverse portfolio of products and services to consumers and businesses in the United States, South Asia, East Asia, Africa, Europe and Latin America. Its growth strategy includes acquisition, innovation and market development.

FEXD is a Delaware corporation based in Collegeville, Pennsylvania. The company was launched in May 2021 by a management team led by Dr. Saiful Khandaker that has extensive experience in developing and managing financial service platforms and applications, primarily in the mobile money sector. FEXD is sponsored by Revofast LLC.

Acquisition Targets

In September 2022, FEXD announced definitive agreements for business combinations with Rana Financial Inc., a Georgia corporation, and Mobitech International LLC (dba Afinoz), a limited liability company organized in the United Arab Emirates. The agreements call for Rana and Afinoz to become wholly owned subsidiaries of FEXD, with the combined company expected to continue trading on the Nasdaq under existing ticker symbol ‘FEXD’. The mergers are expected to close in Q2 2023.

Rana Financial

Rana Financial is a licensed money transfer company founded in 2009. Rana provides fast and affordable online and mobile transfer of funds between the U.S. and Latin America. Rana has been providing money transfer services in the U.S. market for 13 years and has 30,000 active users. Rana’s money transfer business grew to 200,000 transactions in 2021. The merger agreement values Rana at an implied $78 million enterprise value.

Mobitech International LLC

Mobitech International LLC (dba Afinoz) is an artificial intelligence-enabled digital lending platform used by India’s leading banks, non-banking financial companies and fintech loan providers. Afinoz’s fintech platform supports enterprises making loans primarily to middle- and working-class borrowers via its website or through its mobile phone application. Afinoz’s platform makes loans available and affordable to millions of Indian workers and unbanked users by providing access at a low cost. Afinoz’s platform has more than 50 lending partners, and its database of registered users in India includes more than two million individuals. The merger agreement values Afinoz at an implied $120 million enterprise value.

Market Opportunity

According to analysis by global market research firm Mordor Intelligence, the worldwide financial technology market is valued at approximately $194 billion in 2023 and is projected to grow to nearly $500 billion by 2028, representing a CAGR of 18.97% for the forecast period. According to the report, various financial crises and the COVID-19 pandemic have fueled consumer adoption of, and investor interest in, fintech over the past several years.

Management Team

Dr. Saiful Khandaker is Founder, CEO and President of FEXD. He is Group CEO and founder of FAMA Holdings Inc., a global developer of fintech platforms, applications and services based in the U.S. with offices in the U.K., India, Bangladesh and Zambia. He is currently leading the development of the FAMACASH™ network, a global fintech ecosystem to provide fast, affordable mobile money services in underserved countries such as Bangladesh. Before founding FAMA, Dr. Khandaker spent more than two decades leading the development of software solutions for Fortune 100 companies and startups. He also helped numerous clients modernize their fintech services as Chief Technology Officer at Mi3. He holds a Doctor of Management in Organizational Leadership, a Master of Science in Technology Management, and a Bachelor of Science in Computer Information Systems.

Jenny Junkeer is CFO at FEXD. She is a Chartered Accountant with over 17 years of experience. As CEO of Junkeer New Era Consulting, she leads a team specializing in helping companies launch and optimize business operations in fast-changing industries. She has extensive experience helping organizations scale operations to maximize value. She is an Adjunct Association Professor at Deakin University in Australia, a board member of the Global Health Initiative Foundation, and Director of Implementation at ConnectCV. She holds a Bachelor of Commerce Degree (Honors) from Monash University.

FingerMotion Inc. (FEXD), closed Friday's trading session at $10.49, off by 0.095238%, on 197,806 volume. The average volume for the last 3 months is 197,806 and the stock's 52-week low/high is $9.96/$11.00.

Recent News

• Fintech Ecosystem Development Corp. (NASDAQ: FEXD) - InvestorNewsBreaks - Fintech Ecosystem Development Corp. (NASDAQ: FEXD) Reschedules Special Meeting of Stockholders, Extends Deadline for Share Redemption
• Fintech Ecosystem Development Corp. Announces Adjournment of Special Meeting of Stockholders
• Fintech Ecosystem Development Corp. (NASDAQ: FEXD) Is 'One to Watch'